<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898908</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-1802</org_study_id>
    <secondary_id>2018-002530-20</secondary_id>
    <nct_id>NCT03898908</nct_id>
  </id_info>
  <brief_title>Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain</brief_title>
  <acronym>EBRAIN-MEL</acronym>
  <official_title>Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español Multidisciplinar de Melanoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MFAR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español Multidisciplinar de Melanoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma
      BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1
      will include patients with asymptomatic brain metastases and cohort 2 will include patients
      with symptomatic brain metastasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cohort 1 will include patients with asymptomatic brain metastases and without previous local treatment in the brain (N=48), while cohort 2 will include patients with symptomatic brain metastasis and without previous local treatment in the brain (N=15).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial objective response by RECIST 1.1 before local radiotherapy treatment in cohort 1</measure>
    <time_frame>24 months after start of treatment</time_frame>
    <description>iORR calculated as the proportion of patient with a best overall intracranial response of complete response (CR) or partial response (PR) before local treatment in cohort 1. The final statistical analysis of this endpoint is expected to be performed within 3 months after the local treatment of the last patient in cohort 1. This outcome will be assessed on day 56, and every 8 weeks up to 24 months after start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracranial objective response by RECIST 1.1 before local radiotherapy treatment in cohort 2</measure>
    <time_frame>24 months after start of treatment</time_frame>
    <description>ORR calculated as the proportion of patient with a best overall intracranial response of complete response (CR) or partial response (PR) before local treatment in cohort 1. The final statistical analysis of this endpoint is expected to be performed within 3 months after the local treatment of the last patient in cohort 2. This outcome will be assessed on day 56, and every 8 weeks up to 24 months after start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global intracranial response in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intracranial response in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of global response in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial progression-free survival (PFS) by RECIST 1.1 in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global (intracranial and extracranial) progression-free survival in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients free of progression (intracraneal and extracraneal)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients alive in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 until local treatment in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after local treatment in both cohorts</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Quality of life at week 8 in both cohorts based on the EORTC QLQ 30 scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Compared to baseline evaluation evaluated after 8 weeks since the start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Quality of life at week 24 in both cohorts based on the EORTC QLQ 30 scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared to baseline evaluation evaluated after 24 weeks since the start of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>COMBO450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets
In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>encorafenib</intervention_name>
    <description>Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.
If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death.</description>
    <arm_group_label>COMBO450</arm_group_label>
    <other_name>Braftovi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>binimetinib</intervention_name>
    <description>Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.</description>
    <arm_group_label>COMBO450</arm_group_label>
    <other_name>Mektovi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole brain radiation therapy</intervention_name>
    <description>The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.
Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks.</description>
    <arm_group_label>COMBO450</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgery/stereotactic radiosurgery</intervention_name>
    <description>Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.
Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.
For GTV &gt; 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week.</description>
    <arm_group_label>COMBO450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent of approved by the investigator's Institutional Review Board
             (IRB)/Independent Ethics Committee (IEC), prior to the performance of any trial
             activities.

          -  Histologically confirmed diagnosis of unresectable metastatic cutaneous melanoma, or
             unknown primary melanoma with one or more brain metastasis with a diameter of 10 to 50
             mm, measured by contrast enhanced MRI.

          -  Presence of a BRAF V600E or V600K mutation, or both, in their tumour tissue.

          -  Barthel Index of Activities of Daily Living &gt; 10.

          -  Subjects aged ≥ 18 years.

          -  ECOG 0-1 in asymptomatic patients (cohort 1), 0-2 in symptomatic patients (cohort 2).

          -  Adequate haematological function (Haemoglobin ≥ 9 g/dL, may have been transfused;
             Platelet count ≥ 100 × 109/L; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.)

          -  Adequate hepatic function defined by a total bilirubin level ≤ 2.0 × the upper limit
             of normality (ULN) and AST and ALT levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN
             (for subjects with documented metastatic disease to the liver).

          -  Serum Creatinine ≤ 2.0 x ULN or estimated creatinine clearance ≥ 30 mL/min according
             to the Cockcroft-Gault formula (or local institutional standard method).

          -  Evidence of at least one measurable lesion as detected by radiological or photographic
             methods according to guidelines based on Response Evaluation Criteria in Solid Tumours
             (RECIST) version 1.1.

          -  Naïve untreated patients or patients who have progressed on or after prior first line
             immunotherapy for unresectable locally advanced or metastatic melanoma, but it must
             have ended at least 6 weeks prior to randomization; prior adjuvant therapy is
             permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or
             chemotherapy), BRAF or MEK inhibitors can be used in the adjuvant setting, providing
             the relapse does not occur during the adjuvant treatment or within 12 months after the
             end of it, and providing the adjuvant treatment with targeted therapy did not cause in
             the patient any grade 3-4 toxicity not including medically serious and
             reversible/controlled toxicities (ex: GGT elevation, CPK elevation, vomiting).

          -  Steroids or anticonvulsants are allowed if clinically needed and are not being
             administered in an increasing dose.

          -  Female subjects must either be of non-reproductive potential (ie, post-menopausal by
             history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;
             OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

          -  Normal functioning of daily living activities.

          -  Willingness and ability to attend scheduled visits, follow the treatment schedule and
             undergo clinical tests and other study procedures.

        Exclusion Criteria:

          -  Uveal or mucosal melanoma.

          -  History of leptomeningeal metastases, with the exception that they are only seen in
             brain MRI and the patient has ECOG 0-1 and no neurological symptoms (except for cohort
             2, where symptomatic patients will be allowed if ECOG is 0-2).

          -  Another cancer in the last five years, except for in situ carcinoma of the cervix or
             squamous cell carcinoma of the skin adequately treated or limited basal cell skin
             cancer adequately controlled.

          -  History of or current evidence of central serous retinopathy (CSR), retinal vein
             occlusion (RVO) or history of retinal degenerative disease (RDD).

          -  Any previous systemic chemotherapy treatment, extensive brain radiotherapy, targeted
             therapy for locally advanced unresectable or metastatic melanoma; Immunotherapy
             treatment is allowed but must have ended at least 6 weeks prior to randomization.

          -  History of Gilbert's syndrome.

          -  Previous treatment with a BRAF or MEK inhibitor in metastatic setting. This treatment
             will be allowed in the adjuvant setting (see above). Previous treatments with
             immunotherapy will be allowed in both the metastatic and adjuvant setting.

          -  Known positive serology for human immunodeficiency virus, or an active hepatitis B or
             hepatitis C infection, or both.

          -  Impaired cardiovascular function or clinically significant cardiovascular diseases
             &quot;Clinically significant (i.e., active) cardiovascular disease: cerebrovascular
             accident/stroke (&lt; 6 months prior to enrolment), myocardial infarction (&lt; 6 months
             prior to enrolment), unstable angina, congestive heart failure (≥ New York Heart
             Association Classification Class II), a LVEF &lt; 50% evaluated by MUGA or
             echocardiography, or serious cardiac arrhythmia requiring medication or a triplicate
             average baseline QTc interval &gt; 500 ms.&quot;

          -  Uncontrolled arterial hypertension despite medical treatment.

          -  Moderate (Child Pugh Class B) or severe (Child Pugh Class C) hepatic impairment.

          -  Impairment of gastrointestinal function.

          -  Neuromuscular disorders associated with high concentrations of creatine kinase.

          -  Pregnant or nursing (lactating) women.

          -  Medical, psychiatric, cognitive or other conditions that may compromise the patient's
             ability to understand the patient information, give informed consent, comply with the
             study protocol or complete the study.

          -  Known hypersensitivity to encorafenib, binimetinib or their components.

          -  Persisting toxicity related to prior therapy of Grade &gt;1 NCI-CTCAE v 4.03; however,
             alopecia and sensory neuropathy Grade ≤ 2 is acceptable.

          -  Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ highly effective birth control
             from screening to 180 days after the last dose of study treatment.

          -  Known alcohol or drug abuse.

          -  Inability to swallow tablets or capsules.

          -  Total lactase deficiency or glucose-galactose malabsorption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iván Márquez Rodaz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Berrocal Jaime, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario General de Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Nepote</last_name>
    <phone>+34 93 434 44 12</phone>
    <email>investigacion@mfar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Pablo Luna, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Almudena García Castaño, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>María González Cao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Insular de Canarias</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Delvys Rodríguez Abreu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Pablo Cerezuela, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Eva Muñoz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Ana Arance-Fernández, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Clara Montagut, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Pedro Sánchez Mauriño, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Begoña Campos Balea, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Ainara Soria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. U. Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Ivan Márquez Rodas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Carlos Aguado, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Enrique Espinosa, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Miguel Ángel Berciano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Miguel Fernández de Sanmamed Gutiérrez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Maria del Carmen Álamo de la Gala, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Alfonso Berrocal-Jaime, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Roberto Díaz-Beveridge, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Teresa Puértolas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastases</keyword>
  <keyword>melanoma</keyword>
  <keyword>encorafenib</keyword>
  <keyword>binimetinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

